World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
88
Citations
28806
World Ranking
13149
National Ranking
185

Overview

Albert Parés is affiliated with the University of Barcelona in Spain and has an extensive research portfolio in the field of medicine, with a focus on hepatology. Their work is primarily centered on liver diseases and related immunological responses, treatment methodologies, and diagnostic strategies. Parés' academic contributions span multiple subfields including hepatology, epidemiology, surgery, pulmonary and respiratory medicine, and oncology.

Their main research topics include:

  • Liver Diseases and Immunity
  • Liver Disease Diagnosis and Treatment
  • Pediatric Hepatobiliary Diseases and Treatments
  • Gallbladder and Bile Duct Disorders
  • Drug Transport and Resistance Mechanisms
  • Liver Disease and Transplantation
  • Hepatitis B Virus Studies

Albert Parés has published frequently in several scientific journals, contributing to the body of knowledge in hepatology and related fields. The main publication venues where their work appears are:

  • Journal of Hepatology
  • JHEP Reports
  • The American Journal of Gastroenterology
  • Liver International
  • Gastroenterology

Among their recent notable papers are:

  • Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial (2020, Gastroenterology)
  • A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA (2021, Journal of Hepatology)
  • Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase (2020, The American Journal of Gastroenterology)
  • Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group (2022, Journal of Hepatology)
  • A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA (2020, Journal of Hepatology)

Collaboration forms a significant aspect of Parés' work, evidenced by frequent co-authors contributing substantially to their research output. Key collaborators include:

  • Gideon M. Hirschfield
  • Annarosa Floreani
  • Pietro Invernizzi
  • Christophe Corpechot
  • Douglas Thorburn

Best Publications

  • Simplified criteria for the diagnosis of autoimmune hepatitis

    Elke M. Hennes;Mikio Zeniya;Albert. J. Czaja;Albert Parés

  • EASL Clinical Practice Guidelines: management of cholestatic liver diseases

    Ulrich Beuers;Kirsten M. Boberg;Roger W. Chapman;Olivier Chazouillères

  • EASL Clinical Practice Guidelines on nutrition in chronic liver disease

    Manuela Merli;Annalisa Berzigotti;Shira Zelber-Sagi;Srinivasan Dasarathy

  • Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid

    Albert Parés;Llorenç Caballería;Juan Rodés

  • S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial

    Jose M Mato;Javier Cámara;Javier Fernández de Paz;Llorenç Caballería

  • Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid

    Gideon M. Hirschfield;Andrew Mason;Velimir Luketic;Velimir Luketic;Keith Lindor;Keith Lindor

  • Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial

    Rafael Bañares;Rafael Bañares;Frederik Nevens;Fin Stolze Larsen;Rajiv Jalan

  • Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: An international follow-up study

    Willem J. Lammers;Henk R. van Buuren;Gideon M. Hirschfield;Harry L.A. Janssen

  • Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

    Ulrich H W Beuers;M Eric Gershwin;Robert G Gish;Pietro Luigi Invernizzi

  • Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial

    Albert Parés;Ramón Planas;Miguel Torres;Joan Caballería

  • Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis

    Tobias J. Weismüller;Tobias J. Weismüller;Palak J. Trivedi;Annika Bergquist;Mohamad Imam;Mohamad Imam

  • Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy

    Willem J. Lammers;Gideon M. Hirschfield;Christophe Corpechot;Frederik Nevens

  • Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial.

    Eduard Cabré;Pilar Rodríguez-Iglesias;Joan Caballería;Joan C. Quer

  • Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

    Jimmy Z Liu;Johannes Roksund Hov;Trine Folseraas;Trine Folseraas;Eva Ellinghaus

  • Histological course of alcoholic hepatitis: Influence of abstinence, sex and extent of hepatic damage

    Albert Parés;Joan Caballería;Miquel Bruguera;Miquel Torres

  • Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial

    Albert Parés;Llorenç Caballería;Juan Rodés;Miquel Bruguera

  • Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation.

    K. M. Boberg;A. Bergquist;S. Mitchell;A. Pares

  • Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease

    Sun Gou Ji;Brian D. Juran;Sören Mucha;Trine Folseraas

  • Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury.

    Albert Parés;Josep María Barrera;Joan Caballería;Guadalupe Ercilla

  • Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis

    Jimmy Z. Liu;Johannes Roksund Hov;Trine Folseraas;Eva Ellinghaus

Frequent Co-Authors

Gideon M. Hirschfield
Gideon M. Hirschfield University Health Network
Juan Rodés
Juan Rodés University of Barcelona
Bettina E. Hansen
Bettina E. Hansen University Health Network
Keith D. Lindor
Keith D. Lindor Arizona State University
Cyriel Y. Ponsioen
Cyriel Y. Ponsioen University of Amsterdam
Kris V. Kowdley
Kris V. Kowdley Washington State University
Harry L.A. Janssen
Harry L.A. Janssen Erasmus University Rotterdam
Kirsten Muri Boberg
Kirsten Muri Boberg University of Oslo
Roger W. Chapman
Roger W. Chapman University of Oxford

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring alternative healthcare pathways can open doors to diverse career options within medicine. For those seeking a faster entry point into the healthcare workforce, 6 month lpn program options offer accelerated training to become a Licensed Practical Nurse. This route is ideal for students looking to start working and gaining hands-on experience quickly.

If you're interested in advanced practice roles, there are multiple online options available. Aspiring psychiatric nurse practitioners can consider enrolling in psych np online programs. These programs combine flexibility with in-depth psychiatric and mental health expertise, preparing graduates for high-demand clinical positions.

For those drawn to the administrative side of healthcare, a variety of online degrees offer affordable entry points. Pursuing the cheapest online health science degree helps students save on tuition while building a strong foundation in health systems and policy. For career advancement, consider the cheapest online mha programs, which prepare graduates for leadership roles in hospitals, clinics, and public health organizations.

Best Scientists Citing Albert Parés

Trending Scientists